Biorestorative Therapies Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Biorestorative Therapies Inc 's ROA in the first quarter of 2026?
Biorestorative Therapies Inc recorded a cumulative net loss of $-11 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -193.3%.

However, within the Healthcare sector 849 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4479, from total ROA ranking in the fourth quarter of 2025 at 5188.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	-55.07 %	-66.78 %	-61.28 %	-46.91 %	-42.1 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-11	-14	-13	-11	-12
Return On Assets (TTM)	-193.3 %	-199.43 %	-137.85 %	-93.87 %	-90.91 %
BRTX's Total Ranking	# 4479	# 5188	# 4492	# 4427	# 4482
Total Assets (TTM) in million	5	4	6	9	10
Seq. Total Assets Change	13.74 %	-27.7 %	-33.75 %	-17.53 %	-15.9 %
Seq. Net Income Change	-	-	-	-	-

BRTX's 5 Years Annual ROA >> Back to BRTX Management Effectiveness >> Compare BRTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 43
Sector	# 850
Overall	# 4433

Return On Assets Statistics
High	Average	Low
-28.5 %	-457.83 %	-1087.9 %
(Jun 30 2024)		(Mar 31 2020)

Financial Statements
Biorestorative Therapies Inc 's Assets	$ 5 million	BRTX's Balance sheet
Biorestorative Therapies Inc 's Income	$ -2 million	Quarterly BRTX's Income Statement
BRTX's Income by Division		See BRTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-66.78 %	-1.45 %	-23.05 %	-26.71 %	470.47 %
Total Assets in million	4	12	12	16	22
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-14	-9	-10	-18	-44
Annual Return On Assets	-349.1 %	-73.12 %	-83.61 %	-114.22 %	-200.51 %

BRTX's 5 Years Annual ROA >> Back to BRTX Management Effectiveness >> Compare BRTX ROA to its Competitors

More Return On Assets Ratios
BRTX's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BRTX's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BRTX's Competitors
Subscribers only: Roa for Biorestorative Therapies Inc 's Suppliers
Subscribers only: Return On Assets for BRTX's Customers

You may also want to know
BRTX's Roi	BRTX's Inventory Turnover Ratio	BRTX's Growth Rates	BRTX's Dividend Comparisons
	BRTX's Profitability Ratios	BRTX's Asset Turnover Ratio	BRTX's Dividend Growth
BRTX's Roe	BRTX's Valuation Ratios	BRTX's Financial Strength Ratios	BRTX's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T17:44:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.